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Modular Synthesis of Diverse Natural Product-Like Macrocycles:
Discovery of Hits with Antimycobacterial Activity
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Abstract: A modular synthetic approach was developed
in which variation of the triplets of building blocks used
enabled systematic variation of the macrocyclic scaffolds
prepared. The approach was demonstrated in the synthe-
sis of 17 diverse natural product-like macrocyclic scaffolds
of varied (12–20-membered) ring size. The biological rele-
vance of the chemical space explored was demonstrated
through the discovery of a series of macrocycles with sig-
nificant antimycobacterial activity.
The remarkable biological functions of macrocyclic natural
products have inspired over 100 marketed drugs, predomi-
nantly based on macrocyclic peptides and macrolides.[1,2] Yet,
despite an increasing recognition of their virtues, macrocycles
remain an under-represented compound class in drug discov-
ery.[3] Macrocycles strike a valuable balance between structural
pre-organization, and the flexibility that is needed to target
some challenging binding sites.[1] In addition, macrocyclisation
can increase potency and selectivity dramatically, and improve
physiochemical and pharmacokinetic properties.[1, 2,4] Further-
more, an understanding of molecular properties pertinent to
macrocyclic drug discovery is emerging, together with the de-
terminants of cell permeability.[2, 5] Although macrocycles that
target extended binding sites (e.g. , in viral proteases and poly-
merases) typically lie outside conventional drug-like chemical
space, some bioactive macrocycles (e.g. , some kinase inhibi-
tors) can have similar properties to other small molecule
drugs.[2]
The discovery of bioactive macrocycles has been hampered
by the historic uneven and unsystematic exploration of the rel-
evant chemical space.[6] As a result, there is a paucity of macro-
cycles in established small molecule screening collections. Re-
cently, approaches have been developed for the synthesis of
diverse non-peptidic macrocycles,[7] for example from building
blocks,[8] by ring expansion,[9] and using DNA-templated meth-
ods.[10] In addition, genetically encoded approaches can enable
discovery of bioactive macrocyclic peptides.[11] The value of ap-
proaches to explore the properties of diverse macrocycles is re-
flected in the discovery of macrocyclic antimalarials,[12] angio-
Scheme 1. Envisaged approach to skeletally-diverse macrocycles.
FDIPES=diisopropyl (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)-
silyl ; Ns=o-nitrophenylsulfonyl.
Figure 1. Structures of building blocks. Panel A: Initiating building blocks.
Panel B: Propagating building blocks. Panel C: Terminating building blocks.
Ar=2,4-dimethoxyphenyl.
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genesis inhibitors,[13] histone deacetylase inhibitors,[14] and
blockers of sonic hedgehog signalling.[15]
Previously, we reported the diversity-oriented synthesis of
natural product-like molecules based on >80 diverse molecu-
lar scaffolds.[16] Here, the product scaffolds depended on both
the order and nature of the attachment of pairs of building
blocks to a fluorous-tagged linker. We envisaged that the ex-
ploitation of triplets of building blocks would enable extension
to the synthesis of skeletally diverse macrocycles (Scheme 1).
Thus, iterative attachment of propagating and terminating
building blocks (Figure 1) to a fluorous-tagged initiating build-
ing block 1 (!2) would be followed by macrocyclisation (!3).
We recognised that the fluorous-solid phase extraction[17] (F-
SPE) could enable removal of excess reactants at each stage of
the synthesis, and facilitate decoration of the product macrocy-
cle.
Initially, propagating building blocks were attached to the
fluorous-tagged initiating building blocks 1, 4 and ent-4, fol-
lowed by deacetylation (Scheme 2). In each case, the fluorous-
tagged products (13–17) were isolated after F-SPE.
Next, we determined the competence of alternative classes
of terminating building block. Thus, the N-o-nitrophenylsulfon-
yl amide 8, the N-o-nitrophenylsulfonyl carbamate 9 and the
trifluoromethanesulfonamide 11 were appended to appropri-
ate substrates (13, 15 and 17) (Scheme 3). The ring-closing
metatheses[18] of the dienes 2 and 18 (5 mm) proceeded
smoothly with Hoveyda–Grubbs second generation catalyst in
methyl tert-butyl ether (MTBE) at 55 8C to give the correspond-
ing macrocycles 3 and 19. However, the clean ring-closing
Scheme 2. Attachment of propagating building blocks to fluorous-tagged
initiating building blocks. Methods: A PPh3, DEAD = diethyl azodicarboxy-
late, THF then F-SPE; B NH3 in MeOH. [a] Mass recovery (and purity deter-
mined by 500 MHz 1H NMR spectroscopy) after purification by F-SPE alone.
Scheme 3. Attachment of terminating building blocks and subsequent ring-
closing metathesis. Methods: A PPh3, DEAD, CH2Cl2 then F-SPE; C 1 mol%
Hoveyda–Grubbs second generation catalyst, MTBE, 55 8C then P(CH2OH)3,
Et3N, silica; D PhSH, K2CO3, DMF. [a] Mass recovery (and purity determined
by 500 MHz 1H NMR spectroscopy) after purification by F-SPE alone.
[b] 2 mol% catalyst was used. [c] 5 mol% catalyst and 10 mol% 1,4-benzo-
quinone was used. [d] 2 mol% catalyst and 4 mol% 1,4-benzoquinone was
used. Ar=2,4-dimethoxyphenyl.
Table 1. Synthesis of natural product-like macrocycles (see Figure 2;
Products had R1= FDIPES; R2, R3=Ns; R4=TBS unless stated).
Building
blocks
Attachment of terminating
building block[a]
Metathesis[c]
Mass recovery (purity)[b] Product Yield
[%][d]
E/Z[e]
13, 9 66 (95) 24[f] 33[g] 60:40
13, 10 77 (93) 25[h] 56 65:35
13, 11 57[d] 23[f] 84[g] 30:70
13, 12 93 (>95) 26 76 >98:<2
14, 9 >98 (59) 27 56 60:40
14, 10 76 (94) 28[h] 88 [i]
14, 11 93 (95) 29[h] 78 15:85
14, 12 >98 (83) 30[h] 47 [i]
15, 9 90 (93) 21[f] 34[g] 65:35
15, 10 70[d] 31 60 >98:<2
16, 9 97[d] 32 88 >98:<2
16, 10 95[d] 33 75 >98:<2
16, 11 93[d] 34 61 >98:<2
16, 12 >98[d] 35 98 70:30
17, 9 92[d] 36 76 25:75
17, 10 90[d] 37 78 70:30
17, 12 99[d] 38[j] 55 (E) ;
15 (Z)
[a] Method A: PPh3, DEAD, CH2Cl2 then F-SPE. [b] Mass recovery (and
purity determined by 500 MHz 1H NMR spectroscopy) after purification by
F-SPE alone. [c] Method C: 2 or 5 mol% Hoveyda-Grubbs second genera-
tion catalyst, 0, 4 or 10 mol% 1,4-benzoquinone, MTBE, 55 8C then
P(CH2OH)3, Et3N, silica (see Supporting Information). [d] Yield after column
chromatography. [e] Determined by 500 MHz 1H NMR spectroscopy.
[f] The product had R1= FDIPES; R2=R3=H after desulfonylation. [g] Yield
over two steps after desulfoylation with PhSH, K2CO3. [h] The geometric
isomers were separable after subsequent desulfonylation. [i] Not deter-
mined at this stage; after desulfonylation, 28 and 30 were separable geo-
metric isomers. [j] The geometrical isomers were separable.
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metathesis of 20 required 10 mol% 1,4-benzoquinone[18b] in
addition to 5 mol% catalyst to give, after treatment with thio-
phenol and potassium carbonate, the macrocyclic carbamate
21 (R1= FDIPES; R2=R3=H) in 34% yield. In a similar vein,
treatment of the diene 22 with 2 mol% catalyst and 4 mol%
1,4-benzoquinone gave the corresponding macrocycle 23 (R1=
FDIPES; R2=R3=H) in 84% yield.
We then investigated the deprotection of the exemplar mac-
rocycles. The attempted deprotection of the macrocycle 3 did
not proceed smoothly. Treatment of 3 with thiophenol and po-
tassium carbonate, followed by F-SPE eluting with MeOH–
water and then methanol, resulted in overall methanolysis of
the macrolactam; presumably, the Ns group promotes thiolysis
of the macrolactam to give a thioester which is subsequently
methanolised. This unwanted reaction did not plague the de-
protection of the corresponding diene 2, nor the larger macro-
lactam 19, and may be attributed to the strain of the macrocy-
clic ring system of 3. In contrast, desulfonylation of the macro-
cycles 21 and 23 proceeded smoothly. It was decided that N-o-
nitrophenylsulfonyl amides would not be exploited as termi-
nating building blocks in the synthesis of the macrocycle li-
brary.
The synthesis of a wide range of macrocyclic scaffolds is
summarised in Table 1 and Figure 2. The cyclisation precursors
were prepared by treatment of a fluorous-tagged substrate
(13–17) and a terminating building block (9, 10, 11 or 12) with
triphenylphosphine and DEAD: the fluorous-tagged product
was generally purified by F-SPE and used without further pu-
rification. The cyclisation precursors were treated with Hovey-
da-Grubbs second generation catalyst (typically 2 mol%), usu-
ally in the presence of 1,4-benzoquinone. In general, the cycli-
sation reactions proceeded smoothly, and macrocyclic prod-
ucts were isolated after column chromatography. The stereose-
lectivity of the metathesis reaction was often high, and, in
many other cases, the geometric isomers were separable after
subsequent desulfonylation.
Crucially, it was demonstrated that a modular synthesis of
macrocyclic scaffolds was possible. By variation of the building
blocks used, 17 different macrocyclic scaffolds were prepared
with ring sizes varying from 12 to 20. The distributions of mac-
rocycle ring sizes and natural product-likeness scores[19] of the
deprotected scaffolds were compared with those of 2435 com-
mercially available[20] 12- to 20-membered macrocycles
(Figure 3). The 17 macrocyclic scaffolds all had positive natural
Figure 2. Structures of the natural product-like macrocycles prepared by ring-closing metathesis (R1= FDIPES; R2=R3=Ns) (see Table 1 for details). Subse-
quently, the products were deprotected and decorated to give final compounds (R1=R3=H; R2=H, cyclopropylcarbonyl, 1-methyl-imidazol-4-yl sulfonyl or 3-
pyridylaminocarbonyl).
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product-likeness scores that reflect their local natural product-
like structural features.
The macrocyclic scaffolds were subsequently deprotected
and decorated (see Scheme 4 for an example). For example,
the macrocycle 32 (R1= FDIPES; R2=R3=Ns) was treated with
thiophenol and potassium carbonate in DMF, and the resulting
product was purified by F-SPE. The product was then desilylat-
ed (!39c), or decorated prior to desilylation (e.g. !39a or
39b). In total, 66 products based on the 17 macrocyclic scaf-
folds were prepared.
To demonstrate biological relevance, the antimycobacterial
activity of the 66 decorated macrocyclic products was assessed
using Mycobacterium bovis BCG, a model organism for Myco-
bacterium tuberculosis (Supporting Information). In each case,
the bacterium was cultured in the presence of 20 mm macrocy-
cle, and cell viability was assessed by the ability of metabolical-
ly active cells to reduce non-fluorescent resazurin to fluores-
cent resorufin.[21] Under these conditions, the macrocycle 39a
had significant activity, causing 80% growth inhibition.[22] The
IC50 of the macrocycle 39a (IC50=11 mm) was determined, to-
gether with those of a range of analogues: 39b and 39c,
which bear different substituents (IC50=35 and 30 mm respec-
tively) ; the isomeric meta cyclophane 40a (IC50=21 mm) ; and
the ring-contracted analogue 41a (IC50=24 mm) (Figure 4).
Taken together, the initial single concentration and subsequent
concentration-dependent activity determinations suggest that
both the macrocyclic scaffold and the substituents are impor-
tant for biological function. Hits from such phenotypic screens
are highly valuable because they can facilitate the identifica-
tion of new targets for antimycobacterial drug discovery.[23]
Crucially, the macrocycle 39a is highly distinctive from the TB
box set secured from a high-throughput screen of GSK’s collec-
tion:[24] none of the 177 compounds in the box set contains
a macrocyclic ring.
In summary, we have developed a modular approach that
was exploited in the synthesis of 17 diverse natural product-
like macrocyclic scaffolds. Through variation of the triplets of
building blocks used, systematic variation of the scaffolds and
macrocyclic ring size (12–20-membered) was possible. The bio-
logical relevance of chemical space explored was demonstrat-
Figure 3. Macrocycle size and natural product-likeness scores of the 17 de-
protected macrocyclic scaffolds prepared (black dots) and 2435 commercial-
ly-available macrocycles (blue dots).
Scheme 4. Exemplar decoration of a macrocyclic scaffold. Methods: D PhSH,
K2CO3; E urea or sulfonamide formation; F 50% aq. HF, CH2Cl2–MeCN then
Me3SiOMe.
Figure 4. Effect of macrocycles on the viability of M. bovis BCG. Panel
A: Dose-dependent activity of the macrocycle 39a and four analogues.
Panel B: Antimycobacterial activity of selected macrocycles.
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ed through discovery of a series of distinctive macrocycles
with significant antimycobacterial activity.
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A modular approach enabled the syn-
thesis of 17 diverse natural product-like
macrocyclic scaffolds, and the discovery
of a distinctive macrocycles with anti-
mycobacterial activity.
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